GLMD
Price
$0.52
Change
-$0.02 (-3.70%)
Updated
Aug 14 closing price
Capitalization
4.32M
One day until earnings call
Intraday BUY SELL Signals
NVAX
Price
$8.05
Change
-$0.09 (-1.11%)
Updated
Aug 14 closing price
Capitalization
1.33B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GLMD vs NVAX

GLMD vs NVAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GLMD vs. NVAX commentary
Aug 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLMD is a Hold and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2026
Stock price -- (GLMD: $0.52 vs. NVAX: $8.05)
Brand notoriety: GLMD: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLMD: 7% vs. NVAX: 49%
Market capitalization -- GLMD: $4.32M vs. NVAX: $1.33B
GLMD [@Biotechnology] is valued at $4.32M. NVAX’s [@Biotechnology] market capitalization is $1.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $128.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLMD’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • GLMD’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, GLMD is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLMD’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • GLMD’s TA Score: 3 bullish, 6 bearish.
  • NVAX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than GLMD.

Price Growth

GLMD (@Biotechnology) experienced а -12.18% price change this week, while NVAX (@Biotechnology) price change was +1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.51%. For the same industry, the average monthly price growth was -1.43%, and the average quarterly price growth was +2992.28%.

Reported Earning Dates

GLMD is expected to report earnings on Aug 17, 2026.

NVAX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.33B) has a higher market cap than GLMD($4.32M). NVAX has higher P/E ratio than GLMD: NVAX (3.14) vs GLMD (0.02). NVAX YTD gains are higher at: 19.792 vs. GLMD (-30.380). GLMD has higher annual earnings (EBITDA): -7.11M vs. NVAX (-42.13M). NVAX has more cash in the bank: 790M vs. GLMD (19.1M). GLMD has less debt than NVAX: GLMD (41K) vs NVAX (295M). NVAX has higher revenues than GLMD: NVAX (596M) vs GLMD (0).
GLMDNVAXGLMD / NVAX
Capitalization4.32M1.33B0%
EBITDA-7.11M-42.13M17%
Gain YTD-30.38019.792-153%
P/E Ratio0.023.141%
Revenue0596M-
Total Cash19.1M790M2%
Total Debt41K295M0%
FUNDAMENTALS RATINGS
GLMD vs NVAX: Fundamental Ratings
GLMD
NVAX
OUTLOOK RATING
1..100
9318
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6471
P/E GROWTH RATING
1..100
9618
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (25) in the Pharmaceuticals Other industry is somewhat better than the same rating for NVAX (74) in the Biotechnology industry. This means that GLMD’s stock grew somewhat faster than NVAX’s over the last 12 months.

GLMD's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as NVAX (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to NVAX’s over the last 12 months.

GLMD's SMR Rating (99) in the Pharmaceuticals Other industry is in the same range as NVAX (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to NVAX’s over the last 12 months.

GLMD's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as NVAX (71) in the Biotechnology industry. This means that GLMD’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for GLMD (96) in the Pharmaceuticals Other industry. This means that NVAX’s stock grew significantly faster than GLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLMDNVAX
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 19 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GLMD
Daily Signal:
Gain/Loss:
NVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MMLP2.400.11
+4.80%
Martin Midstream Partners LP
IONQ46.261.28
+2.85%
IonQ
ONT17.620.12
+0.69%
Onterris Inc.
AMBP5.23-0.05
-0.95%
Ardagh Metal Packaging SA
REVB1.04-0.07
-6.31%
Revelation Biosciences Inc.

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been closely correlated with XBIO. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLMD jumps, then XBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
-2.34%
XBIO - GLMD
88%
Closely correlated
-0.30%
ELOX - GLMD
57%
Loosely correlated
-1.63%
NVAX - GLMD
35%
Loosely correlated
-1.11%
INDP - GLMD
32%
Poorly correlated
+0.94%
CMMB - GLMD
30%
Poorly correlated
+0.53%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.11%
MRNA - NVAX
52%
Loosely correlated
-0.52%
CRSP - NVAX
43%
Loosely correlated
-0.81%
BNTX - NVAX
40%
Loosely correlated
+1.05%
MRVI - NVAX
38%
Loosely correlated
-1.38%
RXRX - NVAX
38%
Loosely correlated
-4.53%
More